Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 7.58
HPTX's Cash to Debt is ranked higher than
68% of the 1276 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. HPTX: 7.58 )
HPTX' s 10-Year Cash to Debt Range
Min: 0.3   Max: No Debt
Current: 7.58

Equity to Asset 0.73
HPTX's Equity to Asset is ranked higher than
78% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. HPTX: 0.73 )
HPTX' s 10-Year Equity to Asset Range
Min: 0.73   Max: 0.84
Current: 0.73

0.73
0.84
F-Score: 4
Z-Score: 11.30
M-Score: -2.07
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -4.32
HPTX's Operating margin (%) is ranked higher than
82% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -85.54 vs. HPTX: -4.32 )
HPTX' s 10-Year Operating margin (%) Range
Min: -31.79   Max: -3.7
Current: -4.32

-31.79
-3.7
Net-margin (%) -6.12
HPTX's Net-margin (%) is ranked higher than
81% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. HPTX: -6.12 )
HPTX' s 10-Year Net-margin (%) Range
Min: -5.51   Max: 39.4
Current: -6.12

-5.51
39.4
ROE (%) -5.37
HPTX's ROE (%) is ranked higher than
83% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -32.57 vs. HPTX: -5.37 )
HPTX' s 10-Year ROE (%) Range
Min: -4.98   Max: 21.58
Current: -5.37

-4.98
21.58
ROA (%) -3.69
HPTX's ROA (%) is ranked higher than
84% of the 1282 Companies
in the Global Biotechnology industry.

( Industry Median: -26.11 vs. HPTX: -3.69 )
HPTX' s 10-Year ROA (%) Range
Min: -722.57   Max: 17.17
Current: -3.69

-722.57
17.17
ROC (Joel Greenblatt) (%) -486.91
HPTX's ROC (Joel Greenblatt) (%) is ranked higher than
73% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. HPTX: -486.91 )
HPTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -275357.89   Max: -410.04
Current: -486.91

-275357.89
-410.04
» HPTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

HPTX Guru Trades in Q3 2013

RS Investment Management Sold Out
» More
Q2 2014

HPTX Guru Trades in Q2 2014

Jim Simons 34,400 sh (New)
» More
Q3 2014

HPTX Guru Trades in Q3 2014

Joel Greenblatt 18,109 sh (New)
Jim Simons 118,000 sh (+243.02%)
» More
Q4 2014

HPTX Guru Trades in Q4 2014

Jim Simons 250,646 sh (+112.41%)
Joel Greenblatt 12,557 sh (-30.66%)
» More
» Details

Insider Trades

Latest Guru Trades with HPTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 43.86
HPTX's Forward P/E is ranked higher than
88% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. HPTX: 43.86 )
N/A
P/B 6.70
HPTX's P/B is ranked higher than
67% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 6.46 vs. HPTX: 6.70 )
HPTX' s 10-Year P/B Range
Min: 3.09   Max: 6.86
Current: 6.7

3.09
6.86
P/S 8.30
HPTX's P/S is ranked higher than
81% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 31.20 vs. HPTX: 8.30 )
HPTX' s 10-Year P/S Range
Min: 4   Max: 516.4
Current: 8.3

4
516.4
PFCF 29.90
HPTX's PFCF is ranked higher than
96% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. HPTX: 29.90 )
HPTX' s 10-Year PFCF Range
Min: 13.22   Max: 40.65
Current: 29.9

13.22
40.65
POCF 29.48
HPTX's POCF is ranked higher than
94% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. HPTX: 29.48 )
HPTX' s 10-Year POCF Range
Min: 12.81   Max: 38.51
Current: 29.48

12.81
38.51
EV-to-EBIT -156.57
HPTX's EV-to-EBIT is ranked higher than
59% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. HPTX: -156.57 )
HPTX' s 10-Year EV-to-EBIT Range
Min: -194.9   Max: 25.7
Current: -156.57

-194.9
25.7
Current Ratio 5.24
HPTX's Current Ratio is ranked higher than
76% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. HPTX: 5.24 )
HPTX' s 10-Year Current Ratio Range
Min: 0.27   Max: 5.63
Current: 5.24

0.27
5.63
Quick Ratio 5.09
HPTX's Quick Ratio is ranked higher than
77% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. HPTX: 5.09 )
HPTX' s 10-Year Quick Ratio Range
Min: 0.27   Max: 5.63
Current: 5.09

0.27
5.63
Days Inventory 95.02
HPTX's Days Inventory is ranked higher than
91% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. HPTX: 95.02 )
HPTX' s 10-Year Days Inventory Range
Min: 95.12   Max: 108.14
Current: 95.02

95.12
108.14
Days Sales Outstanding 47.76
HPTX's Days Sales Outstanding is ranked higher than
87% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 111.38 vs. HPTX: 47.76 )
HPTX' s 10-Year Days Sales Outstanding Range
Min: 38.22   Max: 47.77
Current: 47.76

38.22
47.77

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.80
HPTX's Price/Net Cash is ranked higher than
79% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 87.00 vs. HPTX: 10.80 )
HPTX' s 10-Year Price/Net Cash Range
Min: 5.13   Max: 5.7
Current: 10.8

5.13
5.7
Price/Net Current Asset Value 9.30
HPTX's Price/Net Current Asset Value is ranked higher than
79% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 28.08 vs. HPTX: 9.30 )
HPTX' s 10-Year Price/Net Current Asset Value Range
Min: 4.5   Max: 5.5
Current: 9.3

4.5
5.5
Price/Tangible Book 7.80
HPTX's Price/Tangible Book is ranked higher than
70% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 9.40 vs. HPTX: 7.80 )
HPTX' s 10-Year Price/Tangible Book Range
Min: 3.83   Max: 5.76
Current: 7.8

3.83
5.76
Price/Median PS Value 0.80
HPTX's Price/Median PS Value is ranked higher than
92% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. HPTX: 0.80 )
HPTX' s 10-Year Price/Median PS Value Range
Min: 0.45   Max: 1.01
Current: 0.8

0.45
1.01
Earnings Yield (Greenblatt) -0.60
HPTX's Earnings Yield (Greenblatt) is ranked higher than
84% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. HPTX: -0.60 )
HPTX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -0.6   Max: 5
Current: -0.6

-0.6
5

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0HY.Germany,
Hyperion Therapeutics Inc., was incorporated in Delaware on November 1, 2006. The Company completed its initial public offering on July 2012. It is a commercial biopharmaceutical company, engaged in the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Its products, RAVICTI (glycerol phenylbutyrate) Oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) Tablets and Powder, are designed to lower ammonia in the blood. The Company has developed RAVICTI to treat urea cycle disorders including 7 of the 8 prevalent UCD subtypes, and is developing glycerol phenylbutyrate, the active pharmaceutical ingredient in RAVICTI, to treat hepatic encephalopathy. RAVICTI is indicated for use as a nitrogen-binding agent for chronic management of adult and pediatric patients above 2 years of age with urea cycle disorders who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. It distributes RAVICTI through two specialty pharmacies with a single dedicated call center responsible for interfacing with patients, physicians and payors. BUPHENYL is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. The Company faces competition from established pharmaceutical and biotechnology companies, as well as from academic institutions, government agencies and private and public research institutions, among others, which may in the future develop products to treat UCD or HE. The Company is subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.
» More Articles for NAS:HPTX

Headlines

Articles On GuruFocus.com
No related article found.


More From Other Websites
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of... Mar 31 2015
Nasdaq stocks posting largest volume increases Mar 31 2015
Window Dressing Hits Stocks In Final-Hour Sell-Off Mar 31 2015
Market set to notch ninth straight quarterly rise Mar 31 2015
Horizon Pharma Upgraded On 'Game Changer' Acquisition Mar 31 2015
Ryan & Maniskas, LLP Announces Investigation of Hyperion Therapeutics, Inc. Mar 31 2015
Horizon Pharma to Buy Hyperion Therapeutics for $1.1B - Analyst Blog Mar 31 2015
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of HYPERION THERAPEUTICS INC. of... Mar 31 2015
Big Pharma Merger Monday Deals Disregard Biotech Bubble Talks Mar 31 2015
Cantor Fitzgerald Downgrades Hyperion After Acquisition Mar 31 2015
Strength Seen in Horizon Pharma (HZNP): Stock Rises 18.2% - Tale of the Tape Mar 31 2015
Hyperion Therapeutics downgraded by Needham Mar 31 2015
Euro Slides on Greece as Oil Falls While Europe Stocks Pare Gain Mar 31 2015
Five Firms Take Lead in Health-Care Deal Flurry: Business of Law Mar 30 2015
Harwood Feffer LLP Announces Investigation of Hyperion Therapeutics, Inc. Mar 30 2015
Cramer Remix: In all my years, never seen this! Mar 30 2015
Stocks: Dow up 264, back in the black for '15 Mar 30 2015
Biz Break: Brisbane biotech bought for $1.1 billion as boom barrels on Mar 30 2015
Asian Futures Jump Amid Global Rally; Crude, Gold Decline Mar 30 2015
Horizon Pharma buying Hyperion for about $1.1 billion Mar 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK